Glyciphage-PG 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Pioglitazone 15mg, formulated for sustained release to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity in adipose tissue, muscle, and the liver. The combination targets multiple pathophysiological defects of type 2 diabetes, offering a comprehensive approach to glycemic management. Glyciphage-PG 1 Tablet SR is indicated for patients inadequately controlled on monotherapy or dual therapy, facilitating improved glycemic control while minimizing the risk of hypoglycemia and gastrointestinal side effects associated with immediate-release formulations. It should be used under medical supervision with regular monitoring of blood glucose, renal and hepatic function. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to any component. Patient adherence to lifestyle modifications alongside therapy is essential for optimal outcomes.